SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4049Denner runs a hedge fund. Harvey Berger is a MD, and did run a Biotech company. tktom-12/15/2015
4048Sorry sport, I do not post on iHub.tktom-12/15/2015
4047that is the infamous biotech_researcher tktomizwked-12/15/2015
4046Denner could have filled the CEO spot in a NY Minute if he did NOT plan to sell.civic08801-12/15/2015
4045Sure looks like Ariad will not find a buyer OR a CEO this year, as they indicatetktom-12/14/2015
4044>> But won't those second-line failures eventually become pona patientBiomaven-12/14/2015
4043I hope you're right, Peter. I agree that there's been little on patient kenyonn112/14/2015
4042I also believe Briga will turn out to be a very valuable asset to Ariad, but I jtktom-12/13/2015
4041Shaw wouldn't know about pulmonary tox in the ALTA trial... Mass General wajaybe-12/12/2015
4040Shaw has been cautious on the drug from the very beginning. No particular hints Biomaven-12/12/2015
4039They need to file an NDA before the FDA will consider approving the drug, prioritktom-12/12/2015
4038Not a rumbling but in the post ASCO Alice Shaw interview with Tony Mok she said tktom-12/12/2015
4037Not a rumbling but in the post ASCO Alice Shaw interview with Tony Mok she said mulanoon2007-12/12/2015
4036Denner knows the value of ARIA and whether the stock is at $6 or $16 during B/O civic08801-12/12/2015
4035They need to file an NDA before the FDA will consider approving the drug, priorikenyonn-12/12/2015
4034jaybe, good point. For the first time in Harvey's career, he may have statedtktom-12/12/2015
4033Further to your point...alectinib was approved 9 & 10 months after both triajaybe-12/11/2015
4032OPTIC 2L (pona vs. nilo) trial listed on clinicaltrials.gov... Recruiting in Bejaybe-12/11/2015
4031FWIW, alectinib took 27 months from breakthrough designation (Sep 2013) to appromulanoon2007-12/11/2015
4030Read the whole post: siliconinvestor.comBiomaven-12/11/2015
4029Biomaven, thanks. Your post over on iHub had me believe that you thought it was tktom-12/11/2015
4028>>just APPROVED a potential best-in-class competitor to Ariad's '1Biomaven-12/11/2015
4027biolog, please let me assist. The FDA, today, just APPROVED a potential best-intktom-12/11/2015
4026Sorry but this is nothing real new.biolog-12/11/2015
4025Ariad's '113 won't be approved until Q1 2017 according to harvey bertktom-12/11/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News